首页> 中文学位 >蛋白质组学方法检测膀胱移行细胞癌患者尿液中特异性肿瘤标记物
【6h】

蛋白质组学方法检测膀胱移行细胞癌患者尿液中特异性肿瘤标记物

代理获取

目录

文摘

英文文摘

引言

第一章材料与方法

第二章结果

第三章讨论

第四章结论

第五章参考文献

第六章文献综述

攻读学位期间的研究成果

致谢

学位论文独创性声明及学位论文知识产权权属声明

展开▼

摘要

Objective: To detect the different protein expression in the urine of bladder transitional cell carcinoma (TCC), pick out new tumor markers, and explore the correlation between those proteins and the pathogenesis of TCC and the clinical application of proteomics methods for the early noninvasive diagnosis of TCC. Methods: Urine samples from 12 TCC patients and the control group (including 4patients with TCC undergoing TUR-BT (transurethral resection of bladder tumor) or partial cystectomy previously, 4 healthy volunteers and 4 renal tumor patients) were analyzed using surface enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) ProteinChip technology. All experimental data were processed by computer to form the simulating maps and the contents of those different proteins would be statistically analyzed. Then the proteins which had been picked out would be identified in Swiss-Prot protein database. Results: Multiple protein changes were reproducibly detected in the urine samples of TCC group and Control group by IMAC-Cu-3 chip, including six potential novel TCC biomarkers and two protein clusters. Among those proteins, 2192Da, 3438Da, 4365Da,5495Da and 8002Da were up-regulated in TCC group, while 4134Da protein and 3660Da-3830Da, 4310Da-5150Da protein clusters were up-regulated in Control group.Combination of the 3438Da and 8002Da biomarkers increased significantly the sensitivity for detecting TCC to 83.3% with a specificity of 66.7%. The 3438Da biomarker had been identified as α-defensin, and the 4310Da-5150Da protein cluster was consistent with gp40 protein in the Swiss-Prot protein database. Conclusion: SELDI-TOF-MS ProteinChip technology is a quick, easy-handling and high-throughput analytic method. This technology can directly screen out relatively specific potential biomarkers from the urine of TCC patients, so it has a better clinical feasibility for early non-invasively diagnosing TCC and will provide some helpful information for predicting the prognosis and studying the pathogenesis of TCC.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号